New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:04 EDTTRVNTrevena initiates TRV734 clinical development
Trevena announced the initiation of its first Phase 1 trial for TRV734. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena’s Phase 2 clinical candidate, TRV130. The main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.
News For TRVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
10:17 EDTTRVNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:06 EDTTRVNTrevena initiated with an Outperform at Cowen
Subscribe for More Information
December 15, 2014
16:34 EDTTRVNCamber Capital reports 7.63% passive stake in Trevena
14:25 EDTTRVNNEA lowers stake in Trevena to 12.8% from 14.8%
Subscribe for More Information
December 12, 2014
16:19 EDTTRVNRA Capital reports 7.9% passive stake in Trevena
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use